Empowering women in pharma industry
Visakhapatnam: women and increasing their representation in the pharmaceutical industry, Pfizer Global Supply's manufacturing unit in Visakhapatnam partnered with GITAM.
The officials mentioned on Wednesday that the graduation of the first batch of women as part of the 36-month-long 'Pfizer Autonomous Teams' (PAT) programme aimed at creating employment opportunities for women at the grassroots level.
The industry-academia collaboration is an initiative towards increasing women's representation in science-based fields while providingthem the opportunity to 'earn as they learn'. As part of the programme, Pfizer recruits' girl students locally to join its manufacturing workforce, while supporting them in continuing their education at the institution. The first cohort of 44 women students graduated from the institution with a degree in B.Sc Chemistry, specialising in Microbiology. At present, over 340 women students are part of the PAT programme in Pfizer's manufacturing unit, Visakhapatnam.
Commenting on the initiative, B Muralidhar Sharma, Vice President (Site Head), Pfizer said, 'As part of our commitment to providing learning opportunities for local women and increasing their representation in science and healthcare, this empowering programme offers a unique opportunity to all participating students.'
Dr. Errol D'Souza, Vice Chancellor, GITAM said, 'It is courageous of the students to balance work and regular education. By combining academic learning with hands-on industry experience, the programme showcases the power of academia-industry collaboration.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
5 days ago
- Hans India
60 international students graduate in various streams
Visakhapatnam: Celebrating the achievements of international students from Kenya, Rwanda, Bhutan, Nigeria, Nepal, Ethiopia, Uganda, and other nations, GITAM hosted its sixth special graduation ceremony here on Wednesday. Highlighting the growing appeal of India's higher education system among international students, Registrar D. Gunasekharan emphasised that India's educational landscape is rich in diversity, culture, and history makes it a preferred global destination for academic pursuits. The institution's School of Pharmacy Principal Srinivas urged graduates to apply their acquired knowledge towards the development of human capital in their home countries. He encouraged them to pursue research-oriented careers to better serve society. GIMSR Biochemistry department Professor K Viswa Kalyan congratulated the students and encouraged them to continue learning in order to stay competitive in today's world. Speaking on the internationalisation of education, Director of International Affairs KPC Kishan shared that over 400 students from 43 countries are currently enrolled across various programmes. He acknowledged the Central Government's 'Study in India' initiative for promoting Indian higher education on the global stage. Dr Kishan also reminded the audience that India has historically contributed groundbreaking innovations and discoveries to the world. He invited graduates to join the Indian Alumni Association to stay connected and strengthen professional networks globally. This year, 60 international students successfully completed programmes in engineering, science, pharmacy, paramedical sciences, and management. The ceremony marked a proud moment for both the graduates and the institution, reinforcing the institution's commitment to academic excellence and global collaboration.
Time of India
02-06-2025
- Time of India
Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy
Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy, which could take on rival Merck & Co's best-selling drug Keytruda. The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term focus on experimental cancer treatments and show that its success as Pfizer 's COVID-19 vaccine partner was not a one-off achievement. It also underscores a push across the pharma sector to master a new dual mechanism of action in oncology that activates the immune system - similar to an established drug class including Merck & Co's Keytruda - but which also cuts a tumour's blood supply. BioNTech's German-listed shares surged 16.7% by 1236 GMT to a six-week high. The two companies said in separate statements that the U.S. group will co-develop and co-commercialize BioNTech's drug, BNT327, for multiple solid tumour types. Live Events BioNTech's CEO and co-founder Ugur Sahin said the collaboration will serve "to accelerate and broadly expand BNT327's development to fully realize its potential." The companies said in presentation slides that Bristol Myers was bringing global networks in clinical development and manufacturing to the partnership, among other benefits. BioNTech said in a statement that the partners were seeking to set a new standard of care in the cancer market segment, now dominated by so-called checkpoint inhibitors including Keytruda with $29.5 billion in 2024 sales. Western drugmakers have struck a host of deals to win access to the new drug technology, known as PD-1/VEGF bispecific antibodies, which was pioneered in China. Pfizer last month partnered with China's 3SBio , paying $1.25 billion upfront and up to another $4.8 billion depending on developmental achievements. Merck & Co, whose Keytruda business is under threat from the sector's development push, in November last year licensed an early-stage cancer drug from China-based LaNova Medicines for up to $3.3 billion. "We are now starting to see an industry vote of confidence in the differentiation of this novel mechanism," BMO Capital Markets analysts said in a note. They welcomed BioNTech "partnering with a big pharma name to help manage a broad development plan and potential commercialization". Shares in Instil Bio, which is working with China's ImmuneOnco on a similar compound, soared 24% in U.S. trade on Monday. Summit Therapeutics and China's Akeso have formed another partnership in the development race with a drug candidate called ivonescimab. BioNTech took full ownership of BNT327 through the acquisition of China's Biotheus earlier this year for $800 million upfront and up to $150 million contingent on development achievements. It previously held certain rights in the drug under a 2023 collaboration deal. In addition to an initial payment of $1.5 billion, Bristol plans to pay BioNTech $2 billion in non-contingent anniversary payments through 2028. BioNTech may also earn up to $7.6 billion in development, regulatory and commercial milestones, Bristol said. The companies will share global profits and losses from the drug equally, and joint development and manufacturing costs will also be shared on a 50/50 basis, with some exceptions. BNT327 is being tested as a first-line treatment in extensive stage small cell lung cancer and non-small cell lung cancer. More than 1,000 patients have been treated with the drug to date. Economic Times WhatsApp channel )
&w=3840&q=100)
First Post
30-05-2025
- First Post
Biotech and AI: Is Trump shooting in America's tech foot? China surging ahead of US
The US's policy under the Second Donald Trump Administration has undergone major changes, with experts saying that America is ceding tech dominance to China, which is now aiming to become from imitator to innovator read more Despite President Trump's pledges to boost American dominance in artificial intelligence (AI) and biotechnology, recent policy moves risk undermining US leadership just as China surges ahead. Trump's administration has imposed sweeping restrictions on the export of critical chip design software and advanced semiconductors to China, aiming to choke off Beijing's access to the tools needed for cutting-edge AI development. However, these curbs have prompted China to double down on its domestic innovation efforts, accelerating the development of home-grown AI chips and large language models, and pushing for self-sufficiency in key technologies. STORY CONTINUES BELOW THIS AD At the same time, US funding cuts and freezes for biomedical research—especially at the NIH—are raising alarms among experts, who warn that this could stifle early-stage biotech innovation and allow China to set the pace in life sciences. China now conducts more clinical trials than the US and is rapidly becoming a linchpin in global drug development, licensing new discoveries to American companies and leveraging a decade-long national strategy to dominate biopharma. As the US tightens controls and reduces public investment, it risks 'shooting itself in the tech foot,' potentially ceding ground to China in both biotech and AI at a critical moment in the global innovation race. What's happening in China The world is seeing a big change in science leadership: China has passed US in the number of clinical trials. This is a critical moment in the global race to lead in biotechnology. China's rise is the result of many years of government support, many trained researchers with PhDs, and more use of artificial intelligence (AI) in research. These efforts have helped China move from copying others to leading in biotech innovation. The Wall Street Journal reports that Chinese companies, which used to only make copies of Western medicines, are now creating new treatments and selling them to big international drug companies. A key moment in this shift was Pfizer's recent deal with China's 3SBio Inc. Pfizer agreed to licence a cancer drug called SSGJ-707 for over $6 billion. The deal includes a $1.25 billion upfront payment, up to $4.8 billion in future payments based on progress and a $100 million investment in 3SBio's stock. China's growth in biotech didn't happen on its own. Bayer, a global drug company, has started a life sciences incubator in Shanghai. This shows how much Bayer values China's growing pool of talent and its low-cost, creative way of doing research. Bayer's head of development, Dr Juergen Eckhardt, said Chinese companies are 'getting more and more competitive'. Many people in the pharma investment world agree. STORY CONTINUES BELOW THIS AD Licensing flows reversed: From copying to leading Pfizer's landmark licensing deal is not an outlier. It is part of a fast-expanding trend of Western companies sourcing cutting-edge drug candidates from China. Investment bank Stifel noted that approximately 30 per cent of all licensing deals by major pharma companies in 2023 and 2024 involved Chinese biotech firms, up from just 12 per cent in previous years. This reversal signals a major transformation: China is no longer merely copying Western drugs — it is now creating them. US-based venture capitalists have responded swiftly. Firms like SR One and Lux Capital are not just investing in Chinese biotech but are reorienting their business strategies around it. SR One has built a three-pronged China strategy that includes acquiring Chinese assets, encouraging clinical trials in Asia, and spinning off startups based on Chinese research. According to SR One's CEO Dr Simeon George, some of the molecules being developed in China are 'world-class,' compelling US firms to rethink how and where they place their bets. Verdiva Bio, a UK startup backed by global investors including Forbion and General Atlantic, recently raised $411 million to develop anti-obesity drugs licensed from China's Sciwind Biosciences. This is a telling example of how Chinese innovation is now forming the backbone of new ventures across borders. US slips while China surges Amid China's ascendancy, many American scientists and industry leaders worry that Washington is undermining its own future. In contrast to Beijing's long-term planning, US policy under the Trump administration has leaned toward budget tightening and regulatory overreach, particularly in biomedical funding. Bipartisan commissions have warned that America is ceding ground in what is now a globally strategic domain. These experts argue that the US needs urgent investment and greater coordination in biotech to prevent a long-term erosion of leadership. Yet the response so far has been tepid. The country's fragmented research funding, slow approval timelines and political gridlock have created an increasingly uncompetitive environment. STORY CONTINUES BELOW THIS AD Meanwhile, China is conducting faster, more cost-effective clinical trials thanks to a large population pool and efficient regulatory processes. US investors, like David Yang of Lux Capital, noted that Chinese labs are quicker to act on promising research. Export curbs backfire in AI battle On another front, AI — a core driver of biotech innovation — has become the centre of escalating tech tensions between the US and China. The Biden-era export restrictions on high-end chips from Nvidia have been fully embraced and continued under President Donald Trump. These curbs, meant to prevent China from developing advanced military AI capabilities, are instead spurring massive Chinese efforts to build indigenous alternatives. Nvidia CEO Jensen Huang has criticised the export controls, warning they jeopardise not just US corporate revenues but also long-term strategic influence. In a recent interview with CNBC, Jensen pointed out that China houses half of the world's AI researchers, forming a vast developer ecosystem that is essential for maintaining a global tech edge. He said that cutting off such a large market undercuts America's soft power in tech. The numbers are staggering. Jensen estimated that Nvidia has already lost $8 billion in sales due to the controls, with up to $50 billion annually at stake. He described China as a '$50 billion-a-year opportunity' that could help the US balance its trade deficit and create thousands of high-paying jobs. But the policy, focussed on national security over commerce, has prioritised caution over cash flow. STORY CONTINUES BELOW THIS AD China's response: De-Americanise the tech stack Beijing has not taken the restrictions passively. Instead, it has accelerated its campaign to 'de-Americanise' its technology stack, as declared by President Xi Jinping at an April Politburo study session. The Chinese leader called for breakthroughs in fundamental AI research, domestically produced chips, and software platforms that are independent from Western influence. Sinocism's Bill Bishop noted that Xi's statement clearly signaled an intent to remove US companies like Nvidia from the core of China's digital infrastructure. The strategy aligns with national security goals and longer-term economic sovereignty. Though China's domestic chips still lag behind Nvidia in performance, the government's resolve — and deep coffers — have launched an all-out sprint toward tech self-sufficiency. This means that even if export curbs are relaxed, American companies may have already lost their window of dominance. Nvidia's market share in China, which once stood at 95 per cent, has dropped to 50 per cent and continues to shrink as local competitors like Huawei scale up. Strategic technologies in a Cold War framework Both biotech and AI are now viewed through the lens of national security, not just economic competitiveness. The new tech cold war pits China's long-term, state-driven strategies against America's market-based, often short-term policymaking. The stakes are existential. As AI becomes the engine behind breakthroughs in drug development, materials science and military applications, whoever leads in these fields may shape the rules of the 21st century. Jensen, while highlighting Nvidia's loyalty to US interests, warned that technological dominance cannot be ensured by sanctions alone. Instead, sustained investment in domestic innovation, workforce development and global alliances are needed. 'We want the world to build on American technology stack,' he told CNBC's Jim Cramer. But cutting off half the world's AI developers — in China — from those platforms could prove to be a self-inflicted wound. STORY CONTINUES BELOW THIS AD In biotech, the story is no different. Licensing deals from Chinese firms are already reshaping Western pharmaceutical pipelines. US hesitancy or regulatory isolationism could end up bolstering China's global position further, as both partners and competitors increasingly look East. Call for US action grows louder With bipartisan commissions sounding the alarm, pressure is mounting for Washington to counter China's advances not with bans, but with bold initiatives. These groups are urging a Manhattan Project-scale investment in biotechnology, citing the sector's potential to transform not only medicine but also national security and economic productivity. They are calling for coordinated action across federal agencies, enhanced public-private partnerships and more resilient supply chains. But such a response requires strategic patience — something Washington rarely musters. In contrast, China's leadership is playing the long game, aligning its research, education and industrial policy with an unwavering focus on tech supremacy. If current trends continue, the US risks losing its innovation edge not because China is stealing it, but because America is neglecting it. Trump's policies, while rooted in legitimate national security concerns, may be inadvertently accelerating China's rise by walling off critical markets, talent and partnerships. The verdict: Who's winning the future? The global contest for biotech and AI leadership is no longer speculative — it's already playing out in clinical labs, investment firms and code repositories. China, with its concerted push toward innovation and self-sufficiency, appears to be pulling ahead. The US, meanwhile, risks handicapping itself through underfunding, isolationist trade policies and a lack of cohesive vision. Pfizer's partnership with 3SBio, Nvidia's lost billions and Xi's tech directives all tell a consistent story: the balance of power in high technology is shifting. Whether the US regains its footing or allows this slip to become a fall depends on the choices it makes now. STORY CONTINUES BELOW THIS AD
